CD47 and cancer: The solution to this issue might lie in their combination with immune checkpoint blockade (ICB) therapy, which has gained prominence in recent years and demonstrated immense potential for cancer therapy, with anti-PD-1, anti-CTLA4, anti-CD47 now widely in use as anti-cancer agents [192].